TrialThe Lancet. Infectious diseases2023

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.

Derick Kimathi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.